
    
      This study includes a 36-month Study Drug Treatment Period (3-month treatment cycles), and a
      Safety Follow-up Period (12 weeks following the Month 36 visit). Participants will receive a
      total of twelve injections of the same treatment they received in the lead-in study,
      L-CP07-167 (NCT00635817) either leuprolide acetate 11.25 mg or 30 mg depot formulation. Each
      injection will be administered 3 months apart for up to 36 months of treatment. Study visits
      will occur on Day 1, Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30 and 33 (1st through the 12th
      leuprolide acetate depot injections, respectively), Month 36, and 12 weeks later for the
      Safety Follow-up Visit.
    
  